
Answers to CME examination

Identification No. JC0419

April 2019 issue of the Journal of the American Academy of Dermatology.

Shields BE, Rosenbach M, Brown-Joel Z, Berger AP, Ford BA, Wanat KA. *J Am Acad Dermatol* 2019;80:869-80.

1. e

2. e

***JAAD* Game Changers: Dupilumab therapy provides clinically meaningful improvement in patient- reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)**



Eden Lake, MD
Maywood, Illinois

Capsule Summary

- The substantial patient burden associated with moderate to severe atopic dermatitis demonstrates need for effective therapies.
- Dupilumab resulted in significant and clinically relevant improvements in patient-reported outcomes assessing symptoms and health-related quality of life.
- Dupilumab effects on patient-reported outcomes complemented clinical measures, demonstrating efficacy for atopic dermatitis across multiple domains important to patients.

How did this article change the practice of dermatology?

This study demonstrated significant improvement of atopic dermatitis with dupilumab and established improved outcomes at dosing of 300 mg.¹

Funding sources: None

Conflicts of interest: None disclosed

Accepted for publication October 25, 2018.

Correspondence to: Eden Lake, MD, Dermatology Division, Loyola University Medical Center, 321 N La Grange Rd, La Grange Park, IL 60526-5622. E-mail: Eden.Lake@lumc.edu.

© 2018 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.

<https://doi.org/10.1016/j.jaad.2018.10.051>

REFERENCE

1. Simpson EL, Gadhari A, Worm M, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). *J Am Acad Dermatol*. 2016;75(3):506-515.